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Abstract  There  is  currently  no  consensus  on  the  treatment  sequence  in  chronic  obstructive
pulmonary  disease  (COPD),  although  it  is  recognized  that  early  diagnosis  is  of  paramount  impor-
tance to  start  treatment  in  the  early  stages  of  the  disease.  Although  it  is  fairly  consensual  that
initial treatment  should  be  with  an  inhaled  short-acting  beta  agonist,  a  short-acting  muscarinic
antagonist,  a  long-acting  beta-agonist  or  a  long-acting  muscarinic  antagonist.  As  the  disease
progresses,  several  therapeutic  options  are  available,  and  which  to  choose  at  each  disease
stage remains  controversial.  When  and  in  which  patients  to  use  dual  bronchodilation?  When  to
use inhaled  corticosteroids?  And  triple  therapy?  Are  the  existing  non-inhaled  therapies,  such  as
mucolytic agents,  antibiotics,  phosphodiesterase-4  inhibitors,  methylxanthines  and  immunos-
timulating agents,  useful?  If  so,  which  patients  would  beneﬁt?  Should  co-morbitities  be  taken
into account  when  choosing  COPD  therapy  for  a  patient?This  paper  reviews  current  guidelines  and  available  evidence  and  proposes  a  therapeutic
scheme for  COPD  patients.  We  also  propose  a  treatment  algorithm  in  the  hope  that  it  will  help
physicians to  decide  the  best  approach  for  their  patients.  The  authors  conclude  that,  at  present,
a full  consensus  on  optimal  treatment  sequence  in  COPD  cannot  be  found,  mainly  due  to  disease∗ Corresponding author.
E-mail address: carlos.crobalo@gmail.com (C. Robalo-Cordeiro).
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heterogeneity  and  lack  of  biomarkers  to  guide  treatment.  For  the  time  being,  and  although
some therapeutic  approaches  are  consensual,  treatment  of  COPD  should  be  patient-oriented.
© 2015  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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ne  of  the  main  reasons  that  has  precluded  the  estab-
ishment  of  a  consensus  treatment  sequence  in  chronic
bstructive  pulmonary  disease  (COPD)  is  that  patient  strat-
ﬁcation  is  not  consensual  across  guidelines.1--4 The  ﬁrst
roblem  emerges  with  the  classiﬁcation  by  the  Global  Ini-
iative  for  Chronic  Obstructive  Lung  Disease  (GOLD)  only
istinguishing  two  issues,  symptoms  and  risk,1 which  are
learly  not  sufﬁcient  to  deﬁne  a  patient  with  COPD,
n  extremely  heterogeneous  disease.  The  Spanish  guide-
ines  propose  treatment  based  on  four  clinically  relevant
henotypes,2 but  even  this  approach  presents  heterogene-
ty.  Although  it  is  fairly  consensual  that  initial  treatment
hould  begin  with  an  inhaled  short-acting  beta  agonist
SABA),  a  short-acting  muscarinic  antagonist  (SAMA),  a
ong-acting  beta-agonist  (LABA)  or  a  long-acting  muscarinic
ntagonist  (LAMA),1,2,4,5 when  and  in  which  patients  to  use
ual  bronchodilation,  inhaled  corticosteroids  (ICS)  in  com-
ination  with  bronchodilation,  or  triple  therapy,  remains
ontroversial,6 except  in  patients  with  the  Asthma-COPD
verlap  syndrome  (ACOS),  who  should  be  initially  treated
ith  ICS.7 ICS  have  been  shown  to  have  side  effects,  namely
neumonia,6 and  tuberculosis  and  the  risk  increases  dose-
ependently  with  ICS  use.8
Apart  from  the  above  mentioned  molecules,  other
otentially  useful  non-inhaled  therapies  such  as  mucolytic
gents,  antibiotics,  phosphodiesterase-4  inhibitors  (PDE4i),
ethylxanthines  and  immunostimulating  agents,  are  avail-
ble,  but  again  their  use  is  not  consensual.1--4 Although
ncreasingly  relevant  and  important  to  the  management
f  COPD,  this  paper  does  not  include  a  section  on  non-
harmacological  measures,  which  are  duly  addressed  by
uimarães  et  al.9
This  paper  reviews  current  guidelines  and  available  evi-
ence  and  proposes  a  therapeutic  scheme  for  COPD  patients.
ethods
he  GI  DPOC-Grupo  de  Interesse  na  Doenc¸a Pulmonar
bstrutiva  Crónica  convened  on  December  2014  to  review
nd  discuss  previously  distributed  papers,  scientiﬁc  meet-
ng  presentations,  current  guidelines  and  practices  related
o  the  management  of  COPD.  Papers  had  been  identi-
ed  through  searching  PubMed  with  the  search  terms
‘chronic  obstructive  pulmonary  disease  dual  bronchodila-
ion’’  and  ‘‘chronic  obstructive  pulmonary  disease  triple
herapy’’  with  no  date  limits.  Papers  identiﬁed  as  described
ere  searched  manually.  Distributed  guidelines  were  GOLD
H
a
i
c014,10 GesEPOC  2014,2 NICE  20103 and  The  Canadian  Tho-
acic  Society  recommendations  for  management  of  COPD
007.4 Additional  new  evidence  was  distributed  after  the
eeting,  including  articles  identiﬁed  through  searches  of
he  authors’  own  ﬁles.  Subsequent  discussions  by  email  led
o  the  preparation  of  the  ﬁrst  draft  of  this  paper.  On  Febru-
ry  2015  the  GI-DPOC  convened  again,  and  discussed  the
rst  draft  of  the  paper  in  light  of  GOLD  2015.1 Additional
ew  evidence  was  distributed  after  the  meeting,  including
ecent  articles  identiﬁed  through  searches  of  the  authors’
wn  ﬁles.  Subsequent  discussions  by  email  led  to  the  prepa-
ation  of  the  ﬁnal  text  of  this  paper.  The  ﬁnal  reference  list
as  generated  on  the  basis  of  originality  and  relevance  to
he  scope  of  this  paper.
hould therapy be initiated early?
 clinical  diagnosis  of  COPD  should  be  considered  in  any
atient  who  has  dyspnea,  chronic  cough  or  sputum  pro-
uction,  and  a  history  of  exposure  to  risk  factors  for
he  disease.  Spirometry  is  required  to  establish  a  diagno-
is  of  COPD.1 The  presence  of  a  post-bronchodilator  ratio
f  Forced  Expiratory  Volume  in  1  second  by  Forced  Vital
apacity  (FEV1/FVC)  <  0.70  conﬁrms  the  presence  of  per-
istent  airﬂow  limitation  and  thus  of  COPD  and  a  normal
alue  for  spirometry  effectively  excludes  the  diagnosis  of
linically  relevant  COPD.1 Spirometric  screening  of  asymp-
omatic  individuals  is  not  supported  by  evidence.  However,
n  individuals  over  40  years  old  with  a smoking  history  (>10
ack-years),  spirometry  may  be  performed  with  the  aim  of
arly  diagnosis.5
A  correct  diagnosis  is  mandatory  to  decide  the  best
reatment  approach.11 Therapy  should  be  initiated  in  early
tages  of  the  disease  as  even  patients  in  GOLD  stage  1  (as
eﬁned  by  GOLD  prior  to  2011)  may  respond  to  bronchodila-
ors  with  physiological  and  symptomatic  improvements.12,13
lso,  several  studies  have  reported  improvement  with  bron-
hodilators  in  GOLD  stage  2  patients  (as  deﬁned  by  GOLD
rior  to  2011).14--16 A  study  assessing  the  ability  of  the  GOLD
011  stratiﬁcation17 to  predict  the  clinical  course  of  COPD
howed  that  group  B  had  signiﬁcantly  poorer  survival  than
roup  C,  concluding  that  this  group  warrants  special  atten-
ion,  requiring  additional  assessment  and  treatment.18
The  Canadian  Thoracic  Society  recommends  therapy
hould  be  guided  by  the  degree  of  disability,  lung  func-
ion  and  exacerbations4 whereas  the  National  Institute  for
ealth  and  Care  Excellence  (NICE)  guidelines  propose  ther-
py  based  on  a  variety  of  parameters  such  as  lung  function,
mprovement  in  symptoms,  activities  of  daily  living,  exer-
ise  capacity,  rapidity  of  symptom  relief,  exacerbations,
Optimal  treatment  sequence  in  COPD  
Table  1  Should  therapy  be  initiated  early?
Diagnosis  •  early  diagnosis  is  of
paramount  importance  to
initiate  treatment  in  the
early  stages  of  the  disease
Therapy  GOLD
A  patients
•  monotherapy  with  a
long-acting  bronchodilator
should  be  the  ﬁrst
treatment  choice
Therapy  GOLD
B  patients
•  in  highly  symptomatic
GOLD  B  patients,  dual
bronchodilation  should  be
initiated  as  soon  as  possible
Therapy  in
patients  with
bronchitic  COPD
•  the  choice  of  single  or
dual  bronchodilation  will
depend  on  the  symptoms
•  if  the  patient  is  a  frequent
exacerbator  (≥2
exacerbations/year  or  1
exacerbation  requiring
hospitalization),  ICS  should
be  added
• in  these  patients,
mucolytic  agents  are  also
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tdrugs  to  consider
patient  preference,  side  effects  and  cost.3 According  to  the
GOLD  guideliness,  LAMA  or  LABA  are  alternative  choices  for
group  A  patients  and  the  recommended  ﬁrst  choice  for  group
B  patients,  with  alternative  choice  of  LAMA  +  LABA.1 How-
ever,  dual  bronchodilation  with  a  ﬁxed-dose  combination  of
indacaterol/glycopyrronium  (IND/GLY)  has  been  reported  to
have  clinically  meaningful  and  symptomatic  improvement  in
moderate  to  severe  non-exacerbating  COPD  patients,  who
by  deﬁnition  fall  within  the  B  category.19,20 On  the  other
hand,  there  are  several  potential  advantages  and  beneﬁcial
effects  of  having  a  LABA  +  LAMA  combination  on  the  same
device.21
The  Spanish  guidelines  propose  that  COPD  treatment
should  be  based  on  four  clinical  phenotypes  (non-
exacerbator,  exacerbator  with  emphysema,  exacerbator
with  chronic  bronchitis,  mixed  COPD-asthma)  and  disease
severity,  and  recommend  LABA  +  LAMA  as  an  option  for  all
phenotypes  with  severity  level  >  II  (on  a  scale  of  I to  IV).2
Table  1  summarizes  our  proposals,  suggestions  and  rec-
ommendations  on  diagnosis  and  early  therapy.
ICS and triple therapy
ICS  use  has  unequivocal  beneﬁts  in  asthma,  but  its  position
in  COPD  treatment  is  controversial.11 Different  guidelines
recommend  the  use  of  ICS  or  triple  therapy  in  different
patient  categories  given  that  patient  stratiﬁcation  is  not
consensual  across  guidelines.1--4 The  only  apparent  consen-
sus  is  that  ICS  therapy  alone  is  not  recommended  in  COPD
1--5,22patients, and  even  in  the  treatment  of  exacerbations,
the  recommendation  is  to  add  oral  or  intravenous  cortico-
steroids  and/or  antibiotics,  depending  on  symptom  severity
and  the  existence  of  infection.1 Regardless  of  GOLD  stage,
e
r
g
a41
evere  exacerbations  must  be  managed  properly,  since  mor-
ality  increases  as  they  become  more  frequent,  particularly
hen  these  require  hospital  admission.23
Several  recent  studies  have  investigated  the  beneﬁts  of
CS  on  COPD,15,19--21,24--28 and  the  majority  do  not  support
he  use  of  ICS  in  all  patients.  Two  speciﬁc  groups  of  patients
ay  beneﬁt  from  ICS:  ACOS,7 with  a  reported  prevalence
anging  from  15%  to  55%,  depending  on  age  and  gender,29
hose  patients  cannot  be  treated  with  monotherapy  LABA,
nd  COPD  with  frequent  exacerbations  (≥2/year)  regardless
f  treatment  with  bronchodilators.11 A  very  recent  review
f  available  studies  strongly  recommends  limiting  use  of  ICS
o  a  minority  of  COPD  patients  who  might  beneﬁt  from  it,
nd  suggests  some  indicators  of  likelihood  of  ICS  patients’
esponse.6
Several  questions  remain  regarding  the  use  of  ICS  in  COPD
atients:  (a)  do  all  ICSs  increase  the  risk  of  pneumonia  in
OPD  patients,  or  is  it  dependent  on  drug  class?;11,12,15,25,30
b)  treatment  with  ICS  for  3  years  has  been  reported  to  be
afe,15 but  for  more  prolonged  treatment  the  safety  proﬁle
s  still  unknown;12 (c)  is  the  use  of  a  speciﬁc  ICS  and  its
ose  relevant  to  the  efﬁcacy/safety  ratio?;31 (d)  Randomized
linical  Trials  (RCTs)  use  very  high  doses  of  ICS  --  do  they  have
he  same  safety  and  efﬁcacy  proﬁle  in  lower  doses?;  and  (e)
hould  ICS  be  used  only  in  patients  for  whom  the  beneﬁts
utweigh  the  risks?11 Risks  associated  to  ICS  use  should  be
learly  established  and  balanced  against  its  clinical  beneﬁts
uch  as  exacerbation  control.
As  for  triple  therapy,  its  recommendation  in  COPD
atients  at  risk  of  exacerbations  is  generally  accepted31--35
one  or  more  exacerbations  per  year,  on  average,  for
 consecutive  years).35 Triple  therapy  seems  to  improve
ung  function,  Quality  of  Life  (QoL),28,33 and  hospitaliza-
ion  rates,28 to  provide  greater  reduction  in  airway  wall
hickness33 and  seems  to  confer  beneﬁts  on  cardiovas-
ular  mortality.36 On  the  other  hand,  a  National  Health
ervice  (NHS)  review  concluded  that,  although  triple  ther-
py  decreased  the  hospitalization  rate  due  to  severe/acute
OPD  exacerbations  compared  with  LAMA  monotherapy,
here  was  insufﬁcient  evidence  to  determine  whether
riple  therapy  was  superior  to  dual  bronchodilation.37 Sev-
ral  authors  pointed  out  that  evidence  in  favor  of  triple
herapy  use  is  scarce,  study  results  heterogeneous,22,30,34
nd  the  studies  were  too  short  to  lead  to  any  strong
ecommendations.34 However,  it  should  be  noted  that  future
riple  therapy,  with  all  drugs  in  the  same  device,  may  have
dded  advantages  compared  to  triple  therapy  in  different
evices,  given  the  possible  synergism  between  molecules,
s  already  shown  for  LABA  +  LAMA26 and  ICS  +  LABA.38
Also,  it  has  to  be  taken  into  account  that  triple  therapy  is
xpensive  and  has  its  own  inherent  risks.32 A  recent  review
rom  UK  general  practice  showed  that,  from  2004  to  2009,
he  use  of  triple  therapy  in  all  COPD  degrees  increased:  from
5%  to  59%  in  patients  with  very  severe  COPD,  and  as  much
s  14%  and  19%  in  patients  with  mild  and  moderate  COPD,
espectively.  Up  to  a  third  of  patients  with  mild  or  mod-
rate  COPD  were  on  triple  therapy,  and  the  authors  raise
he  question  of  whether  these  patients  are  indeed  frequent
xacerbators,  and  thus  are  being  treated  according  to  cur-
ent  guidelines.39 These  numbers  are  somewhat  worrying
iven  the  available  evidence,  and  may  indicate  that  ICSs
re  being  over-prescribed  and,  consequently,  patients  are
42  
Table  2  ICS  and  triple  therapy.
ICS  and  triple
therapy
•  proposal  of  therapeutic
scheme  depicted  in  Fig.  1
Recommendation  •  strong  recommendation  for  a
personalized,  patient-oriented
approach,  taking  into  account
each  patient’s  clinical  and
personal  characteristics  and
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severities:  (1)  Breezhaler  has  mechanisms  that  assure  the
Fpreferences
eing  overtreated.  Some  authors  propose  that  ICS  should
e  withdrawn  from  patients  who  do  not  beneﬁt  from  it.
radual  ICS  withdrawal  in  moderate  COPD  patients  does
ot  increase  moderate  to  severe  exacerbations,  although
 greater  decrease  in  lung  function  during  the  ﬁnal  step  of
ithdrawal  was  shown.24
Some  authors  defend  the  position  that,  given  the  risks
ssociated  with  ICS  therapy,  and  the  overall  safety  and
ffectiveness  of  long-acting  bronchodilators,  bronchodila-
ors  without  ICS  should  be  favored  at  all  levels  of  COPD
everity,  except  if  there  is  an  asthma  component  associ-
ted  with  COPD.6 Dual  bronchodilation  with  IND/GLY  may
e  preferable,  since  it  has  demonstrated  superiority  ver-
us  treatment  with  its  monocomponents,  indacaterol  and
lycopyrronium,26 suggesting  the  existence  of  synergistic
ctivity.  The  potential  advantages  and  beneﬁcial  effects  of
aving  a  combination  of  LABA  +  LAMA  on  the  same  device
re:  (1)  prevention  of  disease  progression,  (2)  increased
fﬁcacy  compared  to  single  agents  given  their  different
echanisms  of  action,  (3)  health  status  improvement  by
d
a
m
1. ACOS: asthma component predominant. 2. COPD component predominant.  
FEV1 /FVC <0
FEV1 >50%
Occasional dysp
SABA/SAM
Persistent dysp
Persistent dysp
LABA/LAMA
≤1 e
(or 0 ex
≤1 exacerbation/year
(or 0 exacerbations with hospitalization)
≥2 exacerbations/year
(or 1 exacerbation with hospitalization)
ICS+LABA ou
ICS+LAMA
Pers
ICS+
LLABA+LAMA
igure  1  Proposed  therapeutic  scheme.  From  top  to  bottom:  asthJ.  Ferreira  et  al.
educing  symptoms  and  increasing  physical  activity,  and  (4)
ncreased  compliance  --  once  daily,  same  device.21
GOLD  recommends  dual  bronchodilation  for  symptom
ptimization  as  the  second  treatment  choice  in  B,  C  and
 patients.1
Table  2  and  Fig.  1  summarize  our  proposals,  suggestions
nd  recommendations  on  COPD  treatment  sequence.
ompliance and new molecules
ifﬁculties  in  early  interventions  (GOLD  stage  1  and  2)  are
ainly  due  to  low  compliance,  with  increased  mortality  rate
egardless  of  the  type  of  therapy.12 A  patient  with  dyspnea
nd  fatigue  will  be  more  likely  to  comply  with  treatment
hereas  a  less  symptomatic  patient  will  tend  to  be  non-
ompliant.  Focus  should  be  given  to  informing  patients12,19,20
bout  therapy  beneﬁts.  As  previously  mentioned,  one  of
he  potential  advantages  and  beneﬁcial  effects  of  having
 combination  LABA  +  LAMA  therapy  on  the  same  device  is
n  increased  compliance  --  once  daily.19--21 However,  the
hoice  of  an  inhaler  should  consider  a  range  of  different
actors,  including  price  and  availability,  similarity  to  other
nhalers  the  patient  uses,  ability  for  the  health  care  provider
o  correctly  train  the  patient,  ability  of  the  patient  to  handle
he  inhaler,  and  patient  preference.40 In  this  regard,  studies
ave  shown  some  advantages  of  the  Breezhaler  in  compari-
on  to  the  Handihaler  in  COPD  patients  with  different  diseaserug  is  completely  inhaled  by  the  patient;41 (2)  it  delivers
 higher  ﬁne  particle  fraction  and  generates  a  greater  and
ore  consistent  intrathoracic  deposition42 and  (3)  patients
Asthma drugs
No LABA
monotherapy
ICS and 
LABA 
+/or LAMA
COPD
drugs
1
2
.70
FEV1 <50%
nea
A
nea
nea
xacerbation/year
acerbations with hospitalization)
≥2 exacerbations/year
(or 1 exacerbation with hospitalization)
istent dyspnea
LABA+LAMA
ICS+LABA ou
ICS+LAMA
ABA+LAMA
ma  component  predominant  to  COPD  component  predominant.
Optimal  treatment  sequence  in  COPD  
Table  3  Compliance  and  new  molecules.
Compliance •  proposal  of  focusing  on  patient
information  and  education  to
increase  compliance
•  having  a  combination  of  drugs
on  the  same  device  increases
compliance,  and  the  choice  of  an
inhaler  should  be  based  on  several
factors
New Molecules •  results  not  available
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seem  to  prefer  the  Breezhaler  because  it  is  easier  and  more
comfortable  to  use.41
As  for  the  development  of  new  drugs,  the  combination
of  a  muscarinic  antagonist  with  a  beta2 agonist  (MABA)  is
an  interesting  new  approach,  since  it  has  the  potential  to
demonstrate  additive  or  synergistic  bronchodilation  over
either  component  alone.43 A  phase  I  trial  to  determine  the
pharmacokinetics  of  a  MABA  has  already  been  completed,
but  the  results  are  not  yet  available.44
Table  3  summarizes  our  proposals,  suggestions  and  rec-
ommendations  on  compliance  and  new  molecules.
Additional useful non-inhaled therapies
There  are  a  few  useful  non-inhaled  therapies  that  can  be
used  in  the  management  of  COPD,  namely  mucolytic  agents,
macrolides,  PDE4i,  xanthine  derivatives  and  immunostimu-
lating  agents.  Some  guidelines  have  already  incorporated
these  additional  therapies,1--3,45 but  which  therapy  to  use  in
which  group  of  patients  remains  controversial.
Mucolytic  agents
Carbocysteine,  N-acetylcysteine  (NAC)  and  erdosteine  are
the  most  common  mucolytic  agents  used  in  COPD.  They  all
exhibit  antioxidant  activity,1 with  carbocysteine  and  NAC
being  also  anti-inﬂammatory.46,47 Carbocysteine  seems  to
decrease  exacerbations  in  frequent  exacerbators  not  receiv-
ing  ICS.46,48 High-dose  NAC  seems  to  decrease  exacerbation
frequency  regardless  of  ICS  therapy,47,49 but  only  in  patients
at  high  risk  of  exacerbations.50 This  effect  appears  to  be
particularly  evident  in  patients  with  moderate  COPD,51 but
limitations  due  to  study  population  may  preclude  general-
ization  of  these  conclusions.52,53 Low-dose  NAC  has  no  effect
on  exacerbation  frequency49,54,55 or  clinical  outcomes.54,55
Data  from  a  meta-analysis  supports  the  use  of  erdosteine
in  COPD,  given  the  signiﬁcant  symptom  improvement,56 but
the  reliability  of  this  conclusion  is  disputed.57 The  Span-
ish  guidelines  consider  the  addition  of  carbocysteine  in
the  exacerbator  patient  with  chronic  bronchitis  phenotype
and  severity  level  >  II.2 GOLD  considers  carbocysteine  as  an
option  for  GOLD  D  patients,1 and  the  NICE  guidelines  con-
sider  mucolytic  therapy  for  patients  with  a  chronic  cough
productive  of  sputum,  but  do  not  recommend  routine  use  of
mucolytic  drugs  to  prevent  exacerbations  in  patients  with
stable  COPD.3
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acrolides
acrolides  are  the  most  widely  studied  antibiotics  for  con-
inuous  long-term  or  intermittent  use  in  COPD.58 Available
vidence  supports  the  continuous  use  of  macrolides  to  pre-
ent  exacerbations59--62 and  hospitalizations,62 but  which
atient  population  would  beneﬁt  the  most,  as  well  as  opti-
al  dose  and  duration  of  treatment,  remain  unknown.58,62,63
 small  study  in  patients  with  3  or  more  exacerbations  in
he  previous  year  showed  that  500  mg  azithromycin  3  times
er  week  for  12  months  signiﬁcantly  decreased  exacerbation
ate  and  suggested  that  this  regimen  should  be  considered
or  use  in  patients  with  the  frequent  exacerbator  pheno-
ype  who  are  refractory  to  standard  care.60 However,  a
arge  study  where  250  mg  azithromycin  was  given  to  patients
aily  for  12  months  concluded  that  azithromycin  was  most
ffective  in  preventing  exacerbations  requiring  both  antibi-
tic  and  steroid  treatment,  and  reported  a  greater  efﬁcacy
n  older  patients  and  in  those  with  less  severe  COPD.61 A
ystematic  review  including  only  trials  with  patients  who
ere  frequent  exacerbators  and  who  needed  treatment  with
ntibiotics  or  systemic  steroids  for  those  events,  or  who
ere  on  supplemental  oxygen,  concluded  that  the  impact
f  intermittent  use  of  macrolides  (either  5  days  every  two
onths  or  3  consecutive  days  per  month)  on  exacerba-
ion  frequency  and  quality  of  life  remains  uncertain.59 A
ecent  literature  review  concluded  that,  in  Belgium,  beyond
he  positive  impact  on  exacerbations  and  related  hospi-
alizations,  the  prevention  of  COPD  exacerbations  with
zithromycin  would  not  only  be  cost  saving62 but  also  cost-
ffective.64,65
Two  additional  concerns  regarding  prophylactic  long-
erm  antibiotic  treatment  are  the  possibility  of  developing
ntibiotic  resistance58,59,62,63,66 and  the  unknown  potential
dverse  effects.58,59,63,66
All  current  guidelines  recommend  the  use  of  antibiotics
nly  for  the  treatment  of  infectious  or  severe  exacerba-
ions,  and  do  not  support  the  use  of  prophylactic  antibiotic
herapy.1--5 The  Spanish  guidelines  also  consider  the  addition
f  antibiotics  in  the  exacerbator  with  chronic  bronchitis  phe-
otype  with  severity  level  IV.2 Macrolides  are  one  of  the  ﬁrst
hoice  class  of  antibiotics  to  be  used  when  necessary,1,3--5
ut  teophylline  dose  should  be  reduced  during  macrolide
reatment3,5 since  macrolides  increase  the  serum  concen-
ration  of  theophylline.1
hosphodiesterase-4  inhibitors
lthough  PDE4i  are  currently  not  available  in  Portugal,  its
se  in  COPD  is  already  considered  in  the  Spanish2 and  GOLD1
uidelines.  PDE4i  are  thought  to  reduce  airway  inﬂamma-
ion  and  bronchoconstriction.  A  very  large  systematic  review
oncluded  that  PDE4i  improve  short-term  lung  function  and
educe  exacerbations,  but  have  minimal  or  no  impact  on
aily  symptoms,  QoL  or  life  expectancy.  Moreover,  they
re  associated  with  gastrointestinal  adverse  effects  and
eadaches,  with  roﬂumilast  in  particular  being  associated
ith  signiﬁcant  weight  loss  and  some  psychiatric  symp-
oms.  These  authors  suggest  that  use  of  PDE4i  should  be
imited  to  add-on  therapy  in  a subgroup  of  patients  with
ersistent  symptoms  or  exacerbations  despite  optimal  COPD
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anagement,  and  recognize  that  the  role  of  PDE4i  and  its
ositioning  in  COPD  management  remains  to  be  deﬁned.67
nother  very  large  systematic  review  of  roﬂumilast  reached
he  same  overall  conclusions,  and  further  reported  that
oﬂumilast  signiﬁcantly  reduced  moderate  to  severe  exacer-
ations,  but  not  severe  exacerbations  alone.68 Both  reviews
gree  that  longer-term  trials  are  needed  to  determine  the
ctual  beneﬁts  of  PDE4i  and  their  long-term  safety.  A  more
ecent  study  conﬁrmed  these  results  by  reporting  a  border-
ine  statistical  signiﬁcance  in  the  reduction  of  severe  COPD
xacerbations  with  roﬂumilast  versus  placebo  in  patients
ith  severe  to  very  severe  COPD.69 However,  all  roﬂumi-
ast  results  derived  from  industry-sponsored  trials  have  been
isputed,  with  some  authors  defending  that  these  trials
ere  appropriate70 and  others  criticizing  them.71 A  very
ecent  study  concluded  that,  in  patients  with  severe  chronic
bstructive  pulmonary  disease  at  risk  for  exacerbations,
lready  receiving  ICS  +  LABA,  with  or  without  tiotropium,
oﬂumilast  reduces  exacerbations  and  hospital  admissions,72
nd  these  results  were  corroborated  in  a  small  ‘‘real-life’’
opulation  of  severe  COPD  patients  with  frequent  exacerba-
ions  already  receiving  triple  therapy.73 Roﬂumilast  showed
articular  beneﬁt  in  patients  with  4  or  more  exacerbations
rior  to  initiating  therapy.73
The  Spanish  guidelines  consider  the  addition  of  PDE4i
n  the  ACOS  phenotype  with  severity  level  IV  if  associated
ith  exacerbations  and  sputum,  and  in  the  exacerbator  with
hronic  bronchitis  phenotype  with  severity  level  >  I  PDE4i  are
ne  of  the  recommended  choices.2 GOLD  guidelines  recom-
end  PDE4i  as  alternative  choice  treatments  for  GOLD  C
nd  D  patients,  and  state  that  they  may  be  useful  to  reduce
xacerbations  in  patients  with  FEV1 <  50%  predicted,  chronic
ronchitis,  and  frequent  exacerbations.  Despite  this,  PDE4i
hould  always  be  used  in  combination  with  at  least  one  long-
cting  bronchodilator.1
ethylxanthines
ethylxanthines  are  nonspeciﬁc  inhibitors  of  all  phosphodie-
terase  enzyme  subsets,  and  have  a  wide  range  of  adverse
ffects1 related  to  plasma  concentrations,  including  nau-
ea,  vomiting,  and  headaches  and,  at  higher  concentrations,
ardiac  arrhythmias  and  seizures.74 Theophylline,  the  most
idely  used  methylxanthine,  has  shown  clinically  relevant
esults  in  patients  with  stable  COPD,  namely  FEV1 and  FVC
mprovement,75,76 as  well  as  improvements  in  maximal  O2
ptake  (VO2max),  O2 partial  pressure  (PaO2) and  CO2 partial
ressure  (PaCO2).76 Theophylline  has  a  role  in  the  manage-
ent  of  stable  COPD,  and  is  currently  used  as  add-on  therapy
n  severe  COPD  patients  not  controlled  by  bronchodilator
herapy.74 However,  its  wider  use  is  hampered  by  the  fact
hat  blood  levels  need  to  be  closely  monitored  due  to  seri-
us,  even  potentially  life-threatening  side-effects.75,76 As
or  the  use  of  methylxanthines  in  the  management  of  COPD
xacerbations,  current  evidence  does  not  support  it,  given
hat  the  possible  beneﬁcial  effects  in  lung  function  and  clini-
al  endpoints  are  modest  and  inconsistent,  whereas  adverse
ffects  are  signiﬁcant.77 All  current  guidelines  stand  by  this
oint  of  view.
The  Spanish  guidelines  consider  the  addition  of  theoph-
lline  in  all  phenotypes,  but  only  with  severity  level  IV.2
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OLD  recommends  theophylline  as  an  alternative  choice
reatment  for  all  GOLD  classes,  but  only  if  other  long-term
reatment  bronchodilators  are  unavailable  or  unaffordable.1
he  NICE  guidelines  propose  that  theophylline  should  only  be
sed  after  a  trial  of  short-acting  bronchodilators  and  long-
cting  bronchodilators,  or  in  patients  who  are  unable  to  use
nhaled  therapy.3 The  Canadian  guidelines  only  recommend
rying  theophylline  in  patients  with  severe  symptoms  and
requent  exacerbations  despite  use  of  both  tiotropium  and
 LABA/ICS.4 In  the  management  of  exacerbations,  intra-
enous  methylxanthines  (theophylline  or  aminophylline)  are
onsidered  second-line  therapy,  only  to  be  used  in  selected
ases  when  there  is  insufﬁcient  response  to  short-acting
ronchodilators.1,3,5 When  using  theophylline,  it  is  neces-
ary  to  monitor  blood  levels,  side  effects  and  potential  drug
nteractions.4
mmunostimulating  agents
 few  small  studies  have  reported  a  potential  beneﬁt  of  the
mmunostimulating  agent  OM-85  in  the  prevention  of  severe
espiratory  events,  risk  of  hospitalization  and  duration  of
ospital  stay  in  severe  and  very  severe  COPD  patients,78
nd  in  the  decrease  of  acute  exacerbations,  symptoms,  and
eed  for  antibiotics  and  symptomatic  relief  medications,
n  patients  with  chronic  bronchitis  and  COPD.79 OM-85  was
ell  tolerated.79 In  patients  with  chronic  bronchitis  or  mild
OPD,  a  decrease  in  exacerbation  frequency  was  observed
fter  6  months  of  intermittent  OM-85  administration  (30
ays  followed  by  three  10-day  courses  for  months  3,  4  and  5),
nd  OM-85  was  also  well  tolerated.80 However,  these  studies
ere  small  and  the  longest  follow-up  period  lasted  for  only
 year.
GOLD  does  not  recommend  regular  use  of  immunostimu-
ating  agents  due  to  the  lack  of  studies  on  their  long-term
ffects.1
Table  4  summarizes  our  proposals,  suggestions  and  rec-
mmendations  on  additional  non-inhaled  therapies.
reatment of co-morbidities
here  are  no  conclusive  data  establishing  that  treatment
f  COPD  co-morbidities  will  reduce  morbidity  and  mortal-
ty  rates  in  patients.  The  fact  that  patients  with  clinically
elevant  co-morbidities  are  usually  excluded  from  clini-
al  trials  of  COPD,  and  that  patients  with  COPD  are  also
sually  excluded  from  clinical  trials  on  other  pathologies,
as  prevented  evidence-based  clinical  treatment  guidelines
n  these  patients.  However,  co-morbidities  should  be  ade-
uately  controlled  due  to  their  potential  negative  impact
n  COPD  prognosis.1
ardiovascular  co-morbidities
ardiovascular  medications
 large  retrospective  study  reported  that  statins,
ngiotensin-converting-enzyme  inhibitors  (ACEi),  and
ngiotensin-receptor  blockers  (ARBs)  could  have  cardio-
rotective  properties  in  patients  with  COPD,  substantially
ltering  their  prognosis.  Also,  COPD  hospitalization  and  total
Optimal  treatment  sequence  in  COPD  45
Table  4  Additional  useful  non-inhaled  therapies.
Mucolytic  agents •  seem  to  prevent  exacerbations  in  certain  subtypes  of  COPD  patients
• suggestion  to  use  in  a  patient-oriented  manner
Macrolides •  current  uncertainties  of  long-term  macrolide  use
• proposal  of,  when  considering  this  approach,  continuous  use  is  preferable  to
intermittent  use  and  severe  frequent  exacerbators  are  the  phenotype  of  choice
• decision  should  be  patient-oriented,  considering  the  risk/beneﬁt  ratio  for  each
individual
Phosphodiesterase-4  inhibitors
(PDE4i)
•  identiﬁcation  of  the  group  of  patients  that  could  beneﬁt  the  most  from  PDE4i
remains  elusive
•  proposal  that  this  alternative  should  be  offered  to  more  severe  patients,  frequent
exacerbators  or  with  chronic  bronchitis,  without  low  BMI
• weight  loss  and  gastrointestinal  adverse  effects  should  be  monitored  closely
Methylxanthines  in  COPD
exacerbations
•  current  evidence  does  not  support  their  use  in  the  management  of  COPD
exacerbations
• possible  beneﬁcial  effects  in  lung  function  and  clinical  endpoints  are  modest  and
inconsistent,  whereas  adverse  effects  are  signiﬁcant
• intravenous  methylxanthines  (theophylline  or  aminophylline)  are  considered
second-line  therapy,  only  to  be  used  in  selected  cases  when  there  is  insufﬁcient
response  to  short-acting  bronchodilators
•  when  using  theophylline,  it  is  necessary  to  monitor  blood  levels,  side  effects  and
potential  drug  interactions
Theophylline  for  Stable
COPD
•  to  be  considered  in  all  phenotypes,  but  only  with  severity  level  IV
• recommended  as  an  alternative  choice  treatment  for  all  GOLD  classes,  but  only  if
other long-term  treatment  bronchodilators  are  unavailable  or  unaffordable
• should  only  be  used  after  a  trial  of  short-acting  bronchodilators  and  long-acting
bronchodilators,  or  in  patients  who  are  unable  to  use  inhaled  therapy
• only  recommended  to  try  in  patients  with  severe  symptoms  and  frequent
exacerbations  despite  use  of  both  tiotropium  and  a  LABA/ICS
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GImmunostimulating  agents  •  not  recommended  d
mortality  rates  were  reduced,  as  well  as  the  myocardial
infarction  rate  in  COPD  patients  with  high  cardiovascular
risk,  independently  of  the  concomitant  use  of  steroids.  The
largest  beneﬁts  were  observed  with  the  combination  of
statins  and  either  ACEi  or  ARBs.81 Several  further  studies
were  conducted  to  assess  the  potential  effect  of  statins  and
ACEi  on  COPD,  and  reviews  of  those  studies  concluded  that
they  were  beneﬁcial.82--86 However,  all  these  studies  were
observational,  and  a  very  recent  large  RCT  on  the  effects
of  simvastatin  on  exacerbations  and  FEV1 in  COPD  patients
was  terminated  due  to  futility.87 Other  RCTs  also  failed  to
prove  the  beneﬁts  of  ACEi88 or  ARBs89 in  different  COPD
outcomes.  GOLD  guidelines  do  not  mention  the  use  of  these
medications  and  state  that  cardiovascular  co-morbidities
should  be  treated  according  to  their  speciﬁc  guidelines.1
-Blockers
There  has  been  concern  that  prescription  of  -blockers
for  patients  with  COPD  might  cause  bronchoconstriction
and  worsen  respiratory  symptoms.12 However,  cardioselec-
tive  -blockers  have  been  shown  to  be  associated  with
reduced  mortality  in  patients  with  COPD  undergoing  vascular
surgery,90 and  a  meta-analysis  did  not  ﬁnd  signiﬁcant  dif-
ferences  in  FEV1 or  respiratory  symptoms  between  patients
treated  with  a  cardioselective  -blocker  and  those  treated
with  placebo,  even  in  patients  with  severe  COPD.91 Another
very  recent  meta-analysis  concluded  that  the  use  of  -
blockers  in  patients  with  COPD  with  or  without  co-morbid
e
o
o
r lack  of  studies  on  their  long-term  effects
ardiovascular  diseases,  may  not  only  decrease  the  risk
f  overall  mortality  but  also  reduce  the  risk  of  exacerba-
ions,  concluding  that,  given  the  beneﬁts  of  -blockers  in
onditions  such  as  hypertension,  heart  failure  and  coro-
ary  artery  disease,  these  drugs  should  not  be  withheld
ecause  of  COPD.92 In  a  fairly  large  population  (n  =  825)
f  inpatients  admitted  for  acute  exacerbations  of  COPD,
he  use  of  -blockers  was  well  tolerated  and  associated
ith  reduced  mortality.93 Current  guidelines  recommend
he  use  of  -blockers  to  treat  speciﬁc  associated  co-
orbidities,1,2 preferably  cardioselective  -blockers,1 with
he  added  advantage  of  reducing  exacerbations  and  mortal-
ty  associated  with  some  cardiovascular  co-morbidities.2
astroesophageal  reﬂux  disease  (GERD)
ERD  is  one  of  the  most  common  causes  of  chronic  cough
nd  is  a frequent  co-morbidity  in  COPD  patients,  also  being
ssociated  with  exacerbations.94--96 Older  age  and  female
ender95 are  associated  with  GERD  in  COPD  patients,  and
he  association  between  GERD  and  obesity  is  well  known.  A
ery  recent  large  study  reported  that  COPD  patients  with
ERD  were  at  increased  risk  of  medically  treated  COPD
xacerbations,  deﬁned  as  a  short  course  treatment  with
ral  corticosteroids  alone  or  in  combination  with  antibi-
tics,  only  if  they  did  not  use  acid  inhibitory  treatment
egularly.96 These  results  are  in  accordance  with  a  small
46  
Table  5  Treatment  of  co-morbidities.
Cardiovascular •  cardiovascular  co-morbidities
should  be  treated  according  to
their  speciﬁc  guidelines
• in  the  presence  of  some
cardiovascular  co-morbidities,
cardioselective  beta-blockers
are  not  only  safe  but  also
beneﬁcial  in  the  control  of
COPD
Gastroesophageal
reﬂux disease
(GERD)
•  special  attention  should  be
given  to  older  patients,
women,  and  obese  patients
•  a  proton  pump  inhibitor  is
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inhaled corticosteroids in patients with COPD. Prim Care Respiradvisable
tudy  that  reported  that  proton  pump  inhibitor  use  was  asso-
iated  with  a  signiﬁcant  decrease  in  COPD  exacerbations  in
lder  patients.97 Also,  it  has  been  reported  that  most  of
OPD  medications  except  LAMA  are  associated  with  GERD.95
OLD  guidelines  state  that  proton  pump  inhibitors  are  often
sed  for  treatment  of  GERD,  but  the  most  effective  treat-
ent  for  this  condition  in  patients  with  COPD  has  yet  to  be
stablished.1
Table  5  summarizes  our  proposals,  suggestions  and
ecommendations  on  the  treatment  of  cardiovascular  co-
orbidities  and  GERD.
onclusions
lthough  this  paper  proposes  a  therapeutic  scheme  for  COPD
atients,  a  full  consensus  on  optimal  treatment  sequence
n  COPD  cannot  be  found  at  present.  There  are  still  too
any  unknown  variables,  no  reliable  biomarkers  to  guide
reatment,  and  a  poor  deﬁnition  of  clinically  relevant  COPD
henotypes.  It  is  imperative  that  active  research  continues
n  order  not  only  to  identify  speciﬁc  groups  of  patients  that
an  beneﬁt  from  speciﬁc  treatments,  but  also  to  develop
ew  molecules  or  combinations  of  molecules,  that  are  more
ffective  in  symptom  control.  The  ultimate  goal  would  be
o  stop  disease  progression,  but  this  goal  may  not  be  attain-
ble.  At  present,  COPD  should  be  treated  in  a  personalized,
ailor-made,  patient-oriented  manner.
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